NuCana plc
2.40%
3,430,062
1709626
67022C205
Apr 17, 2025
Apr 18, 2025, 06:04 PM
Reporting Persons (10)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| The Carlyle Group Inc. | CO | 2.40% | 3,430,062 | 0 | 3,430,062 |
| Carlyle Holdings I GP Inc. | CO | 2.40% | 3,430,062 | 0 | 3,430,062 |
| Carlyle Holdings I GP Sub L.L.C. | Other | 2.40% | 3,430,062 | 0 | 3,430,062 |
| Carlyle Holdings I L.P. | Partnership | 2.40% | 3,430,062 | 0 | 3,430,062 |
| CG Subsidiary Holdings L.L.C. | Other | 2.40% | 3,430,062 | 0 | 3,430,062 |
| TC Group, L.L.C. | Other | 2.40% | 3,430,062 | 0 | 3,430,062 |
| Carlyle Investment Management L.L.C. | Other | 2.40% | 3,430,062 | 0 | 3,430,062 |
| Carlyle Genesis UK LLC | Other | 2.40% | 3,430,062 | 0 | 3,430,062 |
| Abingworth LLP | Partnership | 2.40% | 3,430,062 | 0 | 3,430,062 |
| Abingworth Bioventures VII LP | Partnership | 2.40% | 3,430,062 | 0 | 3,430,062 |
Disclosure Items (3)
Ordinary Shares, nominal value (pound)0.04 per share
NuCana plc
3 Lochside Way, Edinburgh, X0, EH12 9DT
Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The information contained on the cover pages is incorporated by reference into this Item 5. The percentage of Ordinary Shares beneficially owned and reported herein is based on 142,037,199 Ordinary Shares outstanding as of December 31, 2024, as disclosed in the Issuer's annual report on Form 20-F filed on March 20, 2025. The securities reported herein include (i) 3,333,333 Ordinary Shares represented by American Depository Shares held of record by Abingworth Bioventures VII LP, (ii) 96,189 Ordinary Shares underlying stock options exercisable within 60 days as of the date hereof, and (iii) 540 Ordinary Shares represented by American Depository Shares held of record by Bali Muralidhar for the benefit of Abingworth Bioventures VII LP and which may be deemed to be beneficially owned by Abingworth Bioventures VII LP. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VII LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record and beneficially owned by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.
The information contained on the cover pages is incorporated by reference into this Item 5.
During the past 60 days, the Reporting Persons have not effected any transactions with respect to the Ordinary Shares.
None.
As of March 20, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding Ordinary Shares.
Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 3: Power of Attorney.